Xenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE)

Key Points

• Unusual options flow: Traders bought 4,063 put options on Xenon on Wednesday, a 2,362% jump above the stock's average daily put volume of 165.
• Analyst sentiment: The consensus rating is "Buy" with a consensus target price of $71.88, though individual targets and ratings vary widely (ranging roughly $58–$90 across firms).
• Insider selling and financials: Insiders sold 296,707 shares worth about $17.85 million over the past three months (insider ownership ~4.07%), and the company reported a quarterly EPS miss of -$1.31 vs. -$1.20 consensus with FY EPS expected around -3.1.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) saw unusually large options trading activity on Wednesday. Stock traders acquired 4,063 put options on the company. This is an increase of 2,362% compared to the average daily volume of 165 put options.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Xenon Pharmaceuticals in a report on Wednesday, April 8th. JPMorgan Chase & Co. boosted their target price on shares of Xenon Pharmaceuticals from $60.00 to $62.00 and gave the stock an "overweight" rating in a report on Friday, January 9th. Wolfe Research assumed coverage on shares of Xenon Pharmaceuticals in a report on Monday, February 23rd. They issued an "outperform" rating and a $60.00 target price for the company. Guggenheim reiterated a "buy" rating and issued a $90.00 target price on shares of Xenon Pharmaceuticals in a report on Monday, March 9th. Finally, Needham & Company LLC boosted their target price on shares of Xenon Pharmaceuticals from $58.00 to $80.00 and gave the stock a "buy" rating in a report on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $71.88.

Xenon Pharmaceuticals Stock Down 0.8%

XENE opened at $58.88 on Thursday. Xenon Pharmaceuticals has a 52-week low of $28.19 and a 52-week high of $63.95. The company has a market cap of $4.90 billion, a P/E ratio of -13.50 and a beta of 0.74. The firm's 50-day moving average price is $50.62 and its 200-day moving average price is $44.96.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.11). During the same quarter in the previous year, the business posted ($0.84) EPS. On average, research analysts anticipate that Xenon Pharmaceuticals will post -3.1 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Andrea Difabio sold 1,342 shares of the company's stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $55.23, for a total value of $74,118.66. Following the completion of the sale, the insider directly owned 7,301 shares of the company's stock, valued at $403,234.23. This represents a 15.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Christopher John Kenney sold 1,410 shares of the business's stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $55.23, for a total transaction of $77,874.30. Following the completion of the transaction, the insider owned 7,069 shares of the company's stock, valued at $390,420.87. This represents a 16.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 296,707 shares of company stock valued at $17,845,365 over the last three months. 4.07% of the stock is owned by company insiders.

Hedge Funds Weigh In On Xenon Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Kestra Advisory Services LLC acquired a new position in shares of Xenon Pharmaceuticals during the fourth quarter valued at about $33,000. Blue Trust Inc. increased its holdings in shares of Xenon Pharmaceuticals by 2,560.7% during the fourth quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company's stock valued at $33,000 after acquiring an additional 717 shares in the last quarter. Danske Bank A S acquired a new position in shares of Xenon Pharmaceuticals during the third quarter valued at about $32,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Xenon Pharmaceuticals during the fourth quarter valued at about $43,000. Finally, Aster Capital Management DIFC Ltd acquired a new position in shares of Xenon Pharmaceuticals during the third quarter valued at about $39,000. Institutional investors and hedge funds own 95.45% of the company's stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company's research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon's scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company's pipeline comprises multiple preclinical and clinical programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.